Group items tagged

Here we discussed Dementia stages & symptoms. Dementia is a wider category of brain diseases. Long term memory loss causes Alzheimer's

Maybe you've heard the term kratom in passing. Maybe you know a little bit about what people say about it but want to do your own research before taking the leap yourself. The following will explore some of the top health benefits of kratom as well as some factors to keep in mind when deciding whether kratom is right for you or not. Kratom is a herbal extract that comes from a type of evergreen tree called Mitragyna speciosa that is native to Southeast Asia. Kratom leaves can be chewed, or they can be dried and swallowed, or brewed into tea. Powdered and liquid supplements are also available on the market. WHY DO PEOPLE TAKE KRATOM? 1. LOW DOSAGE 2. MEDIUM DOSAGE 3. HIGH DOSAGE Kratom has another important effect that probably doesn't apply to everyone equally. Kratom has been used to ease the experience of cutting back on opiates or quitting opiates by minimizing the symptoms of withdrawal. This being said, kratom itself does produce good feelings and bind to opiate receptors in the brain, which means that if you're someone who is susceptible to addiction, you might want to be cognizant of your use and dosage.

Digestive issues such as constipation, dysphagia and irritable bowel syndrome (IBS) may be precursors of Parkinson's disease, according to research published in the journal Gut. Gastrointestinal symptoms are thought to precede the development of some cerebrovascular disease, including brain aneurysm or Alzheimer's disease, and it has been suggested (Braak's hypothesis) that gut conditions may precede the development of Parkinson's disease too. To test this hypothesis, researchers used data from a US nationwide medical record network (TriNetX) to compare 24,624 people who had been diagnosed with Parkinson's disease of unknown cause with those who had been diagnosed with other neurological conditions - Alzheimer's disease (19,046) or cerebrovascular disease (23,942) - or with none of these (24,624; comparison group).

More than three quarters of British people, who have suffered persistent ill health following a Covid-19 infection, have had to cut back or change the work they do, according to a survey on the impact of long Covid published on Wednesday (November 9). In the survey of 1,002 people, conducted by market research company Censuswide, some 98 per cent of long Covid sufferers said the condition had limited their ability to work, with 78 per cent needing to cut back or change their work and 19 having ceased work altogether. Long Covid, a collection of symptoms ranging from pain and heart palpitations to insomnia and brain fog, can last for many months after initial infection. Britain's most recent official labour market data showed that a record proportion of people classified as "economically inactive" - neither working nor looking for a job - were suffering from long-term sickness. In absolute terms, the number of working-age people who are long-term sick has risen by 378,000 since early 2020.

The first big breakthrough in 30 years of Alzheimer's research is providing momentum for clinical trials of "cocktail" treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai and Biogen reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo. The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer's patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. The U.S. Food and Drug Administration is expected to make a decision by early January on the companies' application for accelerated approval. If approved on an accelerated basis, the companies said they would immediately apply for full U.S. regulatory approval which could help secure Medicare coverage.

The menopause is a natural aging process, whereby a woman's oestrogen level drops thus disrupting periods until they eventually stop. A woman is said to be in the menopause when her periods have stopped for 12 months. The age when this usually occurs is between 45-55 but symptoms can begin prior to this. Symptoms vary and not all women experience them all. They include hot flushes, vaginal dryness, joint and muscle pain, insomnia, reduced libido, urinary problems such as bladder weakness or Urinary Tract Infections (UTIs), but this list is not exhaustive. Up to a third of women declare that the menopause affects their quality of life. It is obvious that such physical changes can have an effect on ones well-being. Women going through the menopause are at increased risk of developing depression, low self-esteem and problems with concentration (often called brain fog). There are lots of misconceptions in the public and workplace around menopause as it is a little discussed topic. Did you know 45 per cent of women feel their menopause symptoms have had a negative impact on their work and 47 per cent of women have said that they won't tell their employer if they need to take a day-off from work because of menopausal symptoms? So, with women making up nearly half of the UKs workforce, have you thought about what support your workplace offers for you? And if you are an employer, what could you be doing to support your colleagues who need help during this time?

Recently launched generic version of Apixaban by Teva UK is said to bring savings to the NHS drug bill while making sure patients get the medicine they need. The generic apixaban is available for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Previously there was only a 'branded' product available, but Castleford-based Teva UK succeeded in invalidating the apixaban patent and SPC (supplementary protection certificate) in the UK High Court and so is now able to launch its own 'generic' version - which will bring savings for the NHS while making sure patients get the medicine they need. "We've always said that we stand up for the patient", said Kim Innes, General Manager of Teva UK and Ireland. "The launch of generic apixaban emphasises Teva's commitment to doing the right thing by putting patients at the heart of everything we do by giving them and the NHS access to affordable treatments." Apixaban is an anticoagulant which directly inhibits factor X (factor Xa), inhibiting thrombin formation and the development of thrombi (blood clots). For at-risk patients, such as those with, or at risk for DVT, or NVAF, the risk of stroke related to blood clots forming in the body and traveling to the brain is a serious concern. Each year, DVT affects around 1 person in every 1,000 in the UK and if left untreated, about 1 in 10 people with a DVT will develop a PE.

In what's seen as a major step forward for the treatment of schizophrenia, the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised a new Johnson & Johnson drug in Britain. Byannli is a six-monthly paliperidone palmitate (PP6M) and is the first long-acting injectable schizophrenia treatment which offers patients the potential for up to six months of symptom control and a reduction in their risk of relapse with only two doses a year. It is a long-acting injectable that works by dissolving and entering the bloodstream slowly, due to its extremely low water solubility, resulting in continuous absorption of paliperidone palmitate over a six-month period. "Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication," said Prof David Taylor, director of Pharmacy and Pathology at the Maudsley Hospital.

The new deal struck by the NHS will enable provision of a life-saving treatment for babies and young children who suffer with a rare and fatal genetic disease, metachromatic leukodystrophy (MLD). The revolutionary gene therapy treatment, known by its brand name Libmeldy, is used to treat MLD, which causes severe damage to the child's nervous system and organs, leading to a life expectancy of just five to eight years. Having a reported list price of more than £2.8 million, it is the most expensive drug in the world, but can now be offered to young patients on the NHS in England after the health service negotiated a significant confidential discount. the drug works by removing the patient's stem cells and replacing the faulty gene that causes MLD before then re-injecting the treated cells into the patient. The most common form of MLD usually develops in babies younger than 30 months and can cause loss of sight, speech and hearing, as well as difficulty moving, brain impairment, seizures, and eventually death.

NICE has recommended use of tucatinib as an option to treat HER2-positive breast cancer that has spread in people who have already tried 2 or more anti-HER2 treatments. The move is set to benefit around 400 people with advanced breast cancer. Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading. The medicine is taken as two 150 mg tablets twice daily along with anti-cancer medicines trastuzumab and capecitabine. Helen Knight, programme director in the NICE Centre for Health Technology Evaluation, said: "Unfortunately there is no cure for breast cancer that has spread to other parts of the body. There is also a lack of additional anti‑HER2 treatments which can postpone the need for chemotherapy, especially for people whose cancer has spread to their brain because their treatment options are even more limited.

The Omicron variant of coronavirus is less likely to cause long Covid than previous variants, according to the first peer-reviewed study of its kind from the UK. Researchers at King's College London, using data from nearly 100,000 people who logged their Covid symptoms via an app, found the odds of developing long Covid after infection were 20 per cent to 50 per cent lower during the Omicron wave in the UK compared to Delta. The figure varied depending on the patient's age and the timing of their last vaccination. Long Covid, which includes prolonged symptoms ranging from fatigue to 'brain fog', can be debilitating and continue for weeks or months. It is increasingly being recognised as a public health problem, and researchers have been racing to find out if Omicron presents as big a risk of long Covid as previously dominant variants. The study from King's is believed to be the first academic research to show Omicron does not present as great a risk of long Covid, but that does not mean long Covid patient numbers are dropping, the team said. While the risk of long Covid was lower during Omicron, more people were infected, so the absolute number now suffering is higher. "It's good news, but please don't decommission any of your long Covid services," lead researcher Dr Claire Steves said, appealing to health-service providers.

Japanese drugmaker Eisai said on Tuesday (January 10) it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease. Nearly all previous experimental drugs using the same approach have failed. The company's application to the European Medicines Agency is based on results from a late-stage study in which the drug was shown to slow down the rate of cognitive decline in patients with early Alzheimer's by 27 per cent, compared with a placebo. Eisai also reiterated its plans to apply for marketing authorization of the drug in Japan by the end of its business year on March 31.

We love our partners, and it's likely that we'd do anything for them. We put up with their foibles and we bite our tongue when they do something that annoys us. But often, things can get more serious than that, and action needs to be taken, not just for you, but for them, the rest of the family, and ensuring that you live a long and happy life together. Addiction is becoming a more common problem in relationships and the figures over the last few years have increased significantly with more and more people suffering from problems with alcohol, drugs and gambling. While it's not an easy time for them, nor is it for you, and often they need that little bit of encouragement to take the necessary steps to get addiction counselling and the help they need. Providing that encouragement isn't an easy feat though and it needs to be done carefully. If you're at that point in your relationship where you feel something needs to be done about your partner's addiction, then here are some top tips to help you along your way… DO YOUR RESEARCH The better informed you are about addiction, the more authoritative and helpful you can be when it comes to confronting your partner and discussing the options. There are dozens of in-depth guides, reports and advice columns that can help you understand addiction, from the causes of addiction to the health risks, as well as the impact it has on the brain, and the best forms of rehabilitation for different types of people. By collating all this information, you'll be fully informed and feel confident in approaching your partner.

Early detection and treatment of Alzheimer's disease require the use of dependable and cost-effective screening technologies. Researchers at Sweden's Karolinska Institutet have revealed that the level of tau, a protein that plays a vital role in the development of severe dementia, is associated with a kind of sugar molecule in the blood. The study, which is published in Alzheimer's & Dementia, can pave the way for a simple screening procedure able to predict onset ten years in advance. "The role of glycans, structures made up of sugar molecules, is a relatively unexplored field in dementia research," says the study's first author Robin Zhou, medical student and affiliated researcher at the Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet. "We demonstrate in our study that blood levels of glycans are altered early during the development of the disease. This could mean that we'll be able to predict the risk of Alzheimer's disease with only a blood test and a memory test." In Alzheimer's disease, the neurons of the brain die, which is thought to be a result of the abnormal accumulation of the proteins amyloid beta and tau. Clinical trials for Alzheimer's drugs show that treatment should commence early in the pathological process, before too many neurons have died, to reverse the process before it is too late.

Good news for patients whose epilepsy cannot be controlled by standard anti-seizure drugs! Next month, NHS England will introduce a cutting-edge laser beam therapy that can prevent seizures in these individuals. Known as Laser Interstitial Thermal Therapy (LITT), the advanced treatment targets the part of the brain causing seizures without the need for invasive surgery, the health service said. The new fibre optic laser therapy is being offered at King's College Hospital in London and The Walton Centre in Liverpool. Starting from June, it will be gradually extended to eligible patients across England. Each year, it is expected to benefit up to 50 epilepsy patients in England who are resistant to standard anti-seizure medications. "This groundbreaking new treatment will change the lives of those with severe epilepsy improving quality of life and providing much-needed assurance," said Andrew Stephenson, Minister of State for Health.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Monday (29 January 2024) approved the medicine Rezzayo (rezafungin) to treat invasive candidiasis, an infection caused by a yeast called Candida. Invasive candidiasis can pose a serious health risk as it can affect the blood, heart, brain, eyes, bones and other parts of the body. Napp Pharmaceuticals Ltd was granted the marketing authorisation for the medicine based on phase 3 clinical trial data. In the randomised, double-blind, controlled study, more than half of the invasive candidiasis patients who were given a weekly dose of rezafungin were cured at day 14. Among 94 patients who were given a daily dose of caspofungin (another antifungal treatment), 57 of them were cured during the same time.

Many people with advanced Parkinson's disease are currently required to take more than 20 pills a day to manage their symptoms, while some necessitate treatment through a permanent feeding tube. Soon, patients will only be required to wear a portable kit to get a continuous dose of the medication delivered into their bloodstream 24 hours a day. This innovative treatment, called Produodopa, will now be made available on the NHS, providing benefit to nearly 1,000 people with advanced Parkinson's disease, according to a BBC report. James Palmer, NHS England's medical director for specialised services, told the publication that the drug's rollout will offer "a vital new option on the NHS for those who aren't suitable for other treatments such as deep brain stimulation." He added that the new therapy will help patients manage their symptoms "more effectively" and improve their quality of life.

Researchers from King's College London and the University of Helsinki have identified a link between periodontitis (gum disease) and cryptogenic ischemic stroke, which causes a blockage in the blood vessel supplying blood to a region of the brain. The findings, recently published in the Journal of Dental Research, emphasise severe gum disease as a risk factor for young-onset stroke, particularly in patients with no other identifiable risk factors. Dr. Susanna Paju, Periodontology Specialist from the University of Helsinki, led the study in collaboration with Dr. Svetislav Zaric, Clinical Lecturer in Periodontology from King's College London. Dr. Zaric explains the implications of their research: "Stroke remains the second leading cause of death globally. Strikingly, the incidence and prevalence of ischemic stroke have been increasing in the younger population during past decades," she said. "Periodontitis, which involves deep inflammation of the gums due to bacteria under the gumline, can lead to systemic effects as bacteria enter the bloodstream and affect other parts of the body," she added.

This is not a recent breakthrough, but in our complicated world of new ideas, simplicity is often overlooked. This article points out that magnesium deficiency is a major problem and I think symptoms stemming from magnesium deficiency can be easily overlooked. The article acknowledges an extensive list of symptoms that seem to be rampant in our society. They are: constipation, high blood pressure (hypertension), anxiety, depression insomnia, behavioral disturbances, lethargy impaired memory/thinking, seizures, fatigue, sleep disturbances, pain, muscle cramps, chronic back pain, headaches, migraines, muscular pain, tendonitis, anger, aggression, ADHD, brain fog, tension, anxiety disorders such as OCD. Sounds familiar? What I think is important about this is article is that before we move on to more complex and expensive solutions for any of these problems, we might want to begin with a simple high quality magnesium supplement of your choice. I take it personally, and see the benefits of it in my own ability to rest and focus. Good mechanics always recommend beginning with the simplest solution first, and if that doesn't work, then work your way up to more expensive theories to solve the problem. Today, people often begin with the most expensive theory because they could feel that because their problem is complicated to them, the solution is not simple and they expect to pay more. This is subjective. I suppose the same strategy could be be applied to health.

As your brain learns to create positive thoughts, you will not be able to enjoy sexual intimacy but also other aspects of your life. Please contact us at the following number if you want any more details or if you would like to have a debate on the NLP coaching program.